Please assess the completion status of the following clinical trial:

Trial Title: Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active acromegaly \[serum GH levels above 2.5 μg/liter and/or above 1 μg/liter after oral glucose tolerance test (OGTT) and abnormal IGF-I values\] with a micro- (\<10 mm max tumor diameter) or macroadenoma (\>10 mm max tumor diameter)~* Patients never treated before~* Patients who do not require immediate surgery because of neurological symptoms and/or emergency conditions~* Patients who signed an informed consent to participate to the study.~Exclusion Criteria:~* Patients already treated before with surgery or radiotherapy or with medical treatment~* Patients with mixed GH-PRL adenomas who require combined somatostatin and dopamine treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Newly diagnosed patients with acromegaly

Based on this trial design, predict the completion outcome and termination type (if applicable).